Statistics for Allogene Therapeutics (id:7875 ALLO)
Valuation metrics
Market cap
442.41M
Enterprise value
230.79M
Trailing P/E (ttm)
-1.06
Forward P/E
-1.52
PEG ratio
-1.52
Price/Sales (ttm)
10.29K
Price/Book (mrq)
0.95
Enterprise Value/Revenue
5.37K
Enterprise Value/EBITDA
-0.90
Overview
Shares outstanding
209.67M
Float
151.87M
Shares short
37.04M
% Held by insiders
0.17%
% Held by institutions
0.80%
Average volume (10 days)
2.54M
Average volume (90 days)
Price summary
52-Week low
1.99
52-Week high
5.78
52-Week change
-14.93%
Beta
0.84
50-Day moving average
2.71
200-Day moving average
3.13
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
Ex-dividend date
Last split factor
2:1
Last split date
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
September 30th, 2024
Profitability
Profit margin
0.00%
Operating margin
-625,246.50%
Operational effectiveness
Return on assets
-25.82%
Return on equity
-54.15%
Income statement
Revenue (ttm)
0.00
Revenue per share (ttm)
0.00
Quarterly revenue growth (yoy)
Gross profit (ttm)
0.00
EBITDA
-254,972,992.00
Net income to common (ttm)
-283,428,992.00
Diluted EPS (ttm)
-1.55
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
291.56M
Total cash per share (mrq)
1.39
Total debt (mrq)
92.52M
Total Debt/Equity (mrq)
19.95
Current ratio (mrq)
934.60%
Book value per share (mrq)
2.21
Cash flow
Cash flow statement
-217,308,992.00
Levered free cash flow (LFCF)
-111,507,504.00